Takeda Pharmaceutical Co. Ltd. (TAK): price, analyst ratings, earnings and fundamentals
Updated 16 September 2026, 08:02 ET
Takeda Pharmaceutical Co. Ltd. (TAK) closed at $18.70 on 15 September 2026, up 0.5%. The stock is up 6.1% over one month and up 23.8% over one year. It trades 1.0% below its 52-week high of $18.89. The company last reported on 30 July 2026 for Q1 2026: EPS of $0.48 against an estimate of $0.39, a beat of 23.8%, on revenue of $7.7 billion.
Price and performance
Performance figures use dividend and split adjusted closes over trading sessions, so a one-year move compares the last close with the close 252 sessions earlier. The 52-week range uses the adjusted daily highs and lows of the same window. Read the guide: Momentum, trend and technical indicators.
The live chart with technical indicators is in the app: open TAK in FundSpec.
Analyst ratings
No analyst action on TAK was recorded in the last 90 days; the most recent is from 16 May 2023.
| Date | Firm | Action | Price target |
|---|---|---|---|
| 16 May 2023 | TD Cowen | Maintains Outperform | $30.00 to $20.00 |
| 4 Apr 2023 | TD Cowen | Maintains Outperform | $24.00 to $30.00 |
| 16 Mar 2023 | B of A Securities | Upgrades to Buy from Neutral | $20.00 |
| 19 Jul 2022 | Cowen & Co. | Upgrades to Outperform from Market Perform | $21.00 to $24.00 |
| 7 Oct 2021 | Morgan Stanley | Downgrades to Equal-Weight from Overweight | |
| 11 Mar 2020 | JP Morgan | Maintains Overweight | $31.00 to $30.00 |
| 1 Nov 2019 | Cowen & Co. | Initiates Coverage On Market Perform | $19.50 |
| 24 Sep 2019 | Jefferies | Initiates Coverage On Buy | |
| 19 Mar 2019 | Goldman Sachs | Reinstates Buy |
A price target is one firm's twelve-month view, and the median across firms is a steadier reading than any single call. Upgrades and downgrades matter more when they change a rating, not only a target. Read the guide: What analyst ratings and price targets actually tell you.
Every action with the firm's history is in Analyst Ratings.
Earnings
The next report is scheduled for 29 October 2026 before the open for Q2 2026, with EPS expected at $0.59 on revenue of $7.1 billion. Takeda Pharmaceutical Co. Ltd. beat the EPS estimate in 3 of its last 6 reported quarters.
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Q1 2026 | 30 Jul 2026 | $0.39 | $0.48 | +23.85% | $7.7B |
| Q4 2025 | 13 May 2026 | $0.21 | $0.28 | +35.24% | $7.0B |
| Q3 2025 | 29 Jan 2026 | $0.55 | $0.47 | -13.64% | $7.6B |
| Q2 2025 | 30 Oct 2025 | $0.44 | $0.43 | -2.27% | $7.5B |
| Q1 2025 | 30 Jul 2025 | $0.47 | $0.52 | +11.06% | $7.7B |
| Q4 2024 | 8 May 2025 | $0.16 | $7.0B | ||
| Q3 2024 | 30 Jan 2025 | $0.44 | $7.5B | ||
| Q2 2024 | 31 Oct 2024 | $0.57 | $0.45 | -21.05% | $7.9B |
An earnings surprise is the reported EPS against the consensus estimate on the day. The price reaction depends as much on guidance and on what was already priced in as on the surprise itself. Read the guide: Earnings season: estimates, surprises and price reaction.
Estimates, confirmed dates and alerts for every company are in Earnings.
Fundamentals
On a trailing twelve month basis the company shows revenue growth of 7.45%, a gross margin of 65.51%, an operating margin of 7.48% and a return on equity of 1.52%.
Assets
| Line | Amount |
|---|---|
| Cash & Cash Equivalents | $385,113,000,000 |
| Accounts & Notes Receivable, Net | $709,465,000,000 |
| Inventory | $1,217,349,000,000 |
| Other Current Assets | $159,603,000,000 |
| Total Current Assets | $2,521,192,000,000 |
| Goodwill Intangible Assets, Net | $8,955,990,000,000 |
| Deferred Tax Asset | $370,745,000,000 |
| Total Assets | $14,248,344,000,000 |
Liabilities and equity
| Line | Amount |
|---|---|
| Total Short-term Debt | $548,939,000,000 |
| Other Current Liabilities | $596,283,000,000 |
| Total Current Liabilities | $2,506,521,000,000 |
| Long-term Debt | $4,515,265,000,000 |
| Minority Interest | $895,000,000 |
| Other Liabilities | $82,542,000,000 |
| Total Liabilities | $7,312,365,000,000 |
| Retained Earnings | $1,187,586,000,000 |
| Total Stockholders Equity | $6,935,084,000,000 |
| Total Liability & Stockholders Equity | $14,248,344,000,000 |
Figures as filed with the SEC for the period ended 31 March 2025, in US dollars.
FundSpec fundamental metrics
Each metric is computed from the company's filings and ranked against every company FundSpec covers; the percentile is the share of covered companies with a lower value.
Liquidity
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Cash Ratio | 0.15 | 40th | Calculated as the ratio of Cash and cash equivalents / Current liabilities. This metric calculates the company's ability to repay its short-term debt |
| Current Ratio | 1.01 | 45th | Calculated as the ratio of Current Assets / Current Liabilities. The higher the current ratio, the more capable the company is of paying its obligations |
| Quick Ratio | 0.44 | 30th | Calculated as the ratio of (Cash + Marketable Securities + Accounts Receivable) / Current Liabilities. The quick ratio is a measure of how well a company can meet its short-term financial liabilities. |
Leverage
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Debt/Assets | 0.36 | 77th | Calculated as the ratio of Short-Term Debt + Long-Term Debt / Total Assets. The higher the ratio, the higher the degree of leverage, and consequently, financial risk |
| Debt/Equity | 0.73 | 70th | Calculated as the ratio of Total Liabilities / Shareholders' Equity. The ratio indicates how much debt a company is using to finance its assets relative to the amount of value represented in shareholders’ equity |
| Degree of Combined Leverage | 13.44 | 90th | This ratio summarizes the combined effect that the degree of operating leverage (DOL) and the degree of financial leverage have on earnings per share (EPS), given a particular change in sales |
| Degree of Financial Leverage | 1.67 | 87th | Calculated as the ratio of Percentage change in EPS / Percentage change in EBIT. A higher degree of financial leverage means that the company has more volatile EPS. |
| Degree of Operational Leverage | 8.05 | 88th | Calculated as the ratio of Percentage change in EBIT / Percentage change in revenue. It is a measure of how earnings for the company is impacted by its sales activity. |
| Long Term Debt/Long Term Capital | 0.39 | 50th | Calculated as Long-Term Debt / (Long-Term Debt + Shareholders' Equity). The ratio is an indicator of the company's leverage |
| Long Term Debt/Total Capital | 0.38 | 52nd | Calculated as (Short-Term Debt + Long-Term Debt / (Short-Term Debt + Long-Term Debt + Shareholders' Equity). The ratio is an indicator of the company's leverage |
Earnings Growth (EBIT)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| EBIT Pct Growth | 60.0% | 14th | The EBIT growth rate over the trailing twelve months (TTM) |
Earnings Growth (EBITDA)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| EBITDA Pct Growth | 17.2% | 12th | The EBITDA growth rate over the trailing twelve months (TTM) |
Profitability
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Free Cashflow Margin Pct | 18.7% | 81st | Calculated as the ratio of Free Cashflow from Operating Activities / Net Sales. It measures how much per dollar of revenue the company is able to convert into free cash flow. |
| Gross Margin Pct | 65.5% | 78th | Calculated as the ratio of Revenue - Cost of Goods Sold (COGS) / Revenue. The gross margin represents the percent of total sales revenue that the company retains after incurring the direct costs associated with producing the goods and services sold by a company. |
| Operating Margin Pct | 7.5% | 59th | Calculated as the ratio of (Revenue - (Cost of Goods Sold + Labour + Sales, General & Administrative)) / Revenue. Operating margins are important because they measure efficiency. The higher the operating margin, the more profitable a company's core business is. |
| Operating Profit Pct Growth | 60.0% | 77th | The Operating Profit growth rate over the trailing twelve months (TTM) |
| Operating Profit Pct Growth 3 year CAGR (FY) | -9.4% | 32nd | The Operating Profit compound annual growth rate (CAGR) over the past 3 years |
| Operating Profit Pct Growth 5 year CAGR (FY) | 27.8% | 88th | The Operating Profit compound annual growth rate (CAGR) over the past 5 years |
| PreTax Margin Pct | 3.8% | 50th | Calculated as the ratio of (Gross profit - (Operating Expense + Interest Expense)) / Revenue. The pretax profit margin enables profitability to be compared across companies with significant differences in size, scale, capital structure and tax rates. |
| Return on Assets Pct | 0.7% | 55th | Calculated as the ratio of Net Income / Total Assets. It is an indicator of how efficient the company is at using its assets to generate earnings. |
| Return on Equity Pct | 1.5% | 47th | Calculated as the ratio of Net Income / Shareholders' equity. It is a measure of how much profit a company generates with the money shareholders have invested. |
| Return on Invested Capital Pct | 1.7% | 46th | Calculated as the ratio of (Net Income - Dividends) / (Debt + Equity). It is a measure of how efficient the company is at allocating the capital under its control to profitable investments. |
Cashflow
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| FCF Pct Growth | 58.3% | 75th | The Free Cash Flow growth rate over the trailing twelve months (TTM) |
| FCF Pct Growth 3 year CAGR | -14.3% | 35th | The Free Cash Flow compound annual growth rate (CAGR) over the past 3 years |
| FCF Pct Growth 5 year CAGR | 57.8% | 59th | The Free Cash Flow compound annual growth rate (CAGR) over the past 5 years |
| FCF Return on Assets Pct | 5.8% | 72nd | Calculated as the ratio of Cashflow from Operations / Total Assets. A high cash return on assets means a company is generating more cash flow from every asset dollar |
| Operating Cashflow Pct Growth | 47.6% | 73rd | The Operating Cashflow growth rate over the trailing twelve months (TTM) |
| Operating Cashflow Pct Growth 3 year CAGR (FY) | -2.0% | 39th | The Operating Cashflow compound annual growth rate (CAGR) over the past 3 years |
| Operating Cashflow Pct Growth 5 year CAGR (FY) | 9.6% | 66th | The Operating Cashflow compound annual growth rate (CAGR) over the past 5 years |
Earnings Growth (Net Income)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Net Income Pct Growth | -25.0% | 27th | The Net Income growth rate over the trailing twelve months (TTM) |
| Net Income Pct Growth 3 year CAGR | -22.3% | 24th | The Net Income compound annual growth rate (CAGR) over the past 3 years |
| Net Income Pct Growth 5 year CAGR | 19.5% | 80th | The Net Income compound annual growth rate (CAGR) over the past 5 years |
Top Line Growth
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Revenue Pct Growth | 7.5% | 55th | The Revenue (Sales) growth rate over the trailing twelve months (TTM) |
| Revenue Pct Growth 3 year CAGR | 8.7% | 62nd | The Revenue (Sales) compound annual growth rate (CAGR) over the past 3 years |
| Revenue Pct Growth 5 year CAGR | 6.8% | 49th | The Revenue (Sales) compound annual growth rate (CAGR) over the past 5 years |
Taxes
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Effective Tax Rate Pct | 38.2% | 93rd | The effective tax rate of the company over the trailing twelve months (TTM). |
Margins and returns say how much of each dollar of sales becomes profit and how hard the balance sheet is working; leverage and liquidity say how much room the company has when conditions turn. Read the guide: A practical guide to discounted cash flow valuation.
Fair value, peer multiples and the full statement history are in the app: open TAK in FundSpec.
Insider activity
In the last 90 days insiders filed 64 transactions: 38 acquisitions covering 682,252 shares and 26 disposals covering 740,202 shares. Acquisitions include awards and option exercises as well as open market purchases. The largest by value was a disposal of 16,619 shares by Milano Furuta, Director, Chief Financial Officer on 10 July 2026, worth about $82.0 million at the transaction price.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2 Sep 2026 | Andrew Stewart Plump | Director, President, R&D | Disposal | 116,191 | $18.49 | $2.1M |
| 19 Aug 2026 | Andrew Stewart Plump | Director, President, R&D | Disposal | 19,651 | $18.49 | $363K |
| 18 Aug 2026 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Disposal | 12,980 | $18.11 | $235K |
| 11 Aug 2026 | Elaine Mary Shannon | Pres., Global Supply & Quality | Disposal | 20,363 | $17.55 | $357K |
| 10 Aug 2026 | Andrew Stewart Plump | Director, President, R&D | Disposal | 165,393 | $17.10 | $2.8M |
| 10 Aug 2026 | Julie So-Young Kim | Director, President and CEO | Disposal | 89,090 | $17.10 | $1.5M |
| 10 Aug 2026 | Teresa Marie Bitetti | President, OBU | Disposal | 50,012 | $17.10 | $855K |
| 10 Aug 2026 | Lauren Rusckowski Duprey | Chief Transformation Officer | Disposal | 47,586 | $17.10 | $814K |
| 10 Aug 2026 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Disposal | 33,628 | $17.51 | $589K |
| 10 Aug 2026 | Giles Richard Platford | President, IBU | Disposal | 31,083 | $17.10 | $532K |
| 10 Aug 2026 | Natalie Anne Marie Furney | Global General Counsel | Disposal | 30,868 | $17.10 | $528K |
| 10 Aug 2026 | Gabriele Ricci | Chief Data & Tech. Officer | Disposal | 25,088 | $17.10 | $429K |
| 10 Aug 2026 | Agosti Marcello Pignagnoli | Head, Strat. & Port. Dev | Disposal | 22,957 | $17.10 | $393K |
| 10 Aug 2026 | Rhonda Janice Pacheco | President, U.S. Business Unit | Disposal | 16,901 | $17.10 | $289K |
| 10 Aug 2026 | Awny Samaan Botros Farajallah | Chief Medical Officer | Disposal | 14,006 | $17.10 | $240K |
Insider filings record what officers and directors did with their own shares. Disposals are often planned sales or tax related, so a pattern across several insiders says more than one filing.
SEC filings
The latest filing is a 20-F from 17 June 2026.
| Filed | Form | Document |
|---|---|---|
| 17 Jun 2026 | 20-F | View on sec.gov |
| 25 Jun 2025 | 20-F | View on sec.gov |
| 26 Jun 2024 | 20-F | View on sec.gov |
| 28 Jun 2023 | 20-F | View on sec.gov |
| 29 Jun 2022 | 20-F | View on sec.gov |
| 29 Jun 2021 | 20-F | View on sec.gov |
| 24 Jun 2020 | 20-F | View on sec.gov |
| 27 Jun 2019 | 20-F | View on sec.gov |
Company profile
- Exchange
- NYSE
- Sector
- Pharmaceuticals, Biotech and Chemicals
- Industry
- Pharmaceutical Products
- Chief executive
- Christophe Weber
- Employees
- 47,300
- Website
- takeda.com
- SEC CIK
- 0001395064
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in gastroenterology; oncology; neuroscience; and rare diseases. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig.
Sector and peers
Takeda Pharmaceutical Co. Ltd. is part of the Pharmaceuticals, Biotech and Chemicals sector, which FundSpec tracks across 614 companies.
Companies in the same industry by market capitalization:
PG PROCTER & GAMBLE CoNVO Novo Nordisk A SUL Unilever plcSNY SanofiGSK GSK plcECL Ecolab Inc.ARGX Argenx SeHLN Haleon plc
Put two of them side by side in Compare.
In FundSpec: the fair value estimate, the momentum reading, relative valuation against sector and industry peers, unusual options activity and AI model signals for TAK are available to subscribers, with the same screen in the iOS and Android apps.
Open TAK in FundSpec